Limbal dermoid is a rare congenital lesion that can impair vision and raise aesthetic concerns. Surgery is frequently required to reduce discomfort and enhance visual outcomes. A 20-year-old woman presented with a limbal dermoid measuring 4.5 mm in diameter and half the depth of the stroma. Excision was performed with anterior lamellar keratoplasty (ALK) using a post-Descemet's membrane endothelial keratoplasty graft, which resulted in signs of graft failure. Re-surgery was then performed with post-Descemet's stripping endothelial keratoplasty graft. It yielded a clear graft with good visual acuity. The first corneal graft utilized 95% of the graft thickness to cover 55% of the defect, leading to poor host-donor apposition. The second graft employed 55–65% to cover the same portion of the defect. The proportional thickness of the graft is crucial for a successful ALK. Split cornea transplantation produces respectable results; however, the corneal thickness must be carefully considered.
Background: Basal cell carcinoma (BCC) is the most common skin cancer of the eyelid. The important things management we have to emphasize are to prevent recurrence rate and to get the good cosmetic result after reconstruct the large defect. The aim of this case report is to show the management of both eyelid basal cell carcinoma and large eyelid defect after tumor removal.Methods: Case Report. A Woman 40 years old was reffered from Dermatovenereology Department of Cipto Mangunkusumo Hospital with aggressive type BCC. The location of the tumor was at inferior left eyelid with size of 18 x 19 mm. They planned to perform Mohs’ surgery and consulted to Plastic and Reconstruction division of Ophthalmology Department for eyelid reconstruction. After Mohs’ surgery the horizontal length of the eyelid defect was more than 50% and vertical defect was more than 15 mm. The Mustarde cheek advancement flap were choosen.Results: Post operation necrotic tissue was noted do to ischemic problem. Oral corticosteroid was given with tapering dose for six days. One month later, the condition was improved and Dermatovenereology department performed diode laser for the necrotic tissue and further showing good result.Conclusion: The management for eyelid BCC were still challenging including the technique to reconstruct the large eyelid defect, the risk of recurrence after the tumor removal and post operative result. The dicision to choose the proper technique to reconstruct the eyelid defect and tight follow-up after surgery will give optimal functional and cosmetic result. Keywords: basal cell carcinoma; Mohs surgery; Mustarde cheek advancement flap; necrotizing flap; corticosteroid; diode laser
Background: Central serous chorioretinopathy (CSCR) is an abnormality in posterior segment of theeye, characterized by detachment of retinal neurosensory caused by localized accumulation of serousfluid. CSCR is commonly found in male (90%) with age ranging of 25 to 55 years old and oftenoccurs in white, Asia, and Hispanic. Subretinal fluid will be absorb spontaneously within 3-4 months,thus observation and risk factors modification are the initial management for CSCR for couple ofmonths. However, drugs use on CSCR can be considered to accelerate fluid resorption.Methods: This study is a descriptive-retrospective study, done in Vitreoretina Division of OphthalmologyDepartment, Cipto Mangunkusumo Hospital, Jakarta, from December 2015 to January 2016. Thesubjects were all CSCR patients, using medical records for data selection.Results: There were 90 patients with CSCR, but only 20 eyes from 19 patients could be included tothe study. Most of CSCR patients were male (84%), with age ranging from 25 to 55 years old, meanage of 40.31 years.Conclusion: Management of CSCR in Cipto Mangunkusumo Hospital gave significant improvementin UCVA and CMT.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.